Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
25.97 USD | +1.01% | -0.95% | -14.82% |
09/05 | Intellia Therapeutics' Q1 Net Loss Narrows, Collaboration Revenue Rises | MT |
09/05 | Transcript : Intellia Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-14.82% | 2.48B | |
+64.23% | 55.07B | |
-2.31% | 41.79B | |
+44.36% | 40.22B | |
-8.29% | 28.17B | |
+11.97% | 26.28B | |
-21.16% | 18.93B | |
+7.54% | 13.03B | |
+27.17% | 12.26B | |
+25.72% | 12.21B |
- Stock Market
- Equities
- NTLA Stock
- News Intellia Therapeutics, Inc.
- Wedbush Lowers Price Target for Intellia Therapeutics to $55 From $108, Maintains Neutral Rating